Papers - SATO Atsushi
-
Multicenter Analysis of Hand Foot Syndrome by CapeOx Therapy Using Telephone Support Program after Radical Colon Cancer Surgery
Junichi Koike, Kaoru Furushima, Shin Sasaki, Atsushi Satoh, Kazuteru Watanabe, Mitsunori Ushigome, Tomoaki Kaneko, Hiroyuki Shiokawa, Satoru Kagami, Mari Oba and Kimihiko Funahashi
74 ( 5 ) 287 - 295 2021.5
-
Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin-based or irinotecan-based therapy for colorectal cancer.
Takahashi S, Sakamoto Y, Denda T, Takashima A, Komatsu Y, Nakamura M, Ohori H, Yamaguchi T, Kobayashi Y, Baba H, Kotake M, Amagai K, Kondo H, Shimada K, Sato A, Yuki S, Okita A, Ouchi K, Komine K, Watanabe M, Morita S, Ishioka C
Cancer science 112 ( 4 ) 1567 - 1578 2021.4
-
Evaluation for pharmacokinetic exposure of cytotoxic anticancer drugs in elderly patients receiving (R-)CHOP therapy.
Nakagawa J, Takahata T, Hyodo R, Chen Y, Hasui K, Sasaki K, Saito K, Ueno K, Hosoi K, Terui K, Sato A, Niioka T
Scientific reports 11 ( 1 ) 785 2021.1
-
nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients
M Ueno, T Ioka, A Sato, et al.
Cancer Medicine 24 ( 9 ) 9396 - 9408 2020.10
-
A Case of Non-Resectable Pancreatic Cancer With Multiple Hepatic Metastases Treated With FOLFIRINOX Therapy and Conversion Surgery
Gan To Kagaku Ryoho 46 ( 13 ) 2551 - 2553 2019.12
-
[A Case of Non-Resectable Pancreatic Cancer with Multiple Hepatic Metastases Treated with FOLFIRINOX Therapy and Conversion Surgery].
Akaishi T, Ishido K, Kimura N, Nagase H, Odagiri T, Fujita H, Chen Y, Saito K, Takahata T, Sato A, Hakamada K
Gan to kagaku ryoho. Cancer & chemotherapy 46 ( 13 ) 2551 - 2553 2019.12
-
Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial.
Atsuo Takashima, Kohei Shitara, Kazumasa Fujitani, Keisuke Koeda, Hiroki Hara, Norisuke Nakayama, Shuichi Hironaka, Kazuhiro Nishikawa, Yutaka Kimura, Kenji Amagai, Hirofumi Fujii, Kei Muro, Taito Esaki, Yasuhiro Choda, Toshimi Takano, Keisho Chin, Atsushi Sato, Masahiro Goto, Norimasa Fukushima, Takuo Hara, Nozomu Machida, Manabu Ohta, Narikazu Boku, Masashi Shimura, Satoshi Morita, Wasaburo Koizumi
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 22 ( 1 ) 155 - 163 2019.1
-
癌化学療法施行患者における安全性評価と苦痛度評価の差異に関する患者因子の検討
佐藤温、高畑武功、斎藤絢介 他
癌と化学療法 45 ( 6 ) 955 - 960 2018.6
-
[Analysis of the Patient Factors in the Difference between Adverse Effect Evaluation and Distress Evaluation in Cancer Patients Receiving Chemotherapy].
Tanaka K, Sato A, Takahata T, Kudo F, Saito K, Yu C
Gan to kagaku ryoho. Cancer & chemotherapy 45 ( 6 ) 955 - 960 2018.6
-
GemcitabinおよびS-1治療抵抗性膵癌に対するWeekly Paclitaxel療法の後方視的検討
佐藤温、高畑武功、斎藤絢介、陳豫
癌と化学療法 45 ( 5 ) 817 - 821 2018.5
-
[Retrospective Analysis of Weekly Paclitaxel Chemotherapy for Gemcitabine- and S-1-Resistant Pancreatic Cancer].
Takahata T, Sato A, Yu C, Saito K
Gan to kagaku ryoho. Cancer & chemotherapy 45 ( 5 ) 817 - 821 2018.5
-
A questionnaire survey of pharmacists regarding the clinical practice guidelines for the appropriate use of granulocyte-colony stimulating factors.
Sasaki T, Kato Y, Sato A, Usui N, Baba E, Takano T, Susumu N, Ohnishi K, Nishimoto H, Kiura K
Journal of pharmaceutical health care and sciences 4 2 2018
-
Health-related quality of life in a randomized phase Ⅲ study of gemcitabine plus S-1,S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer:GEST study.
Yasuhiro Hagiwara,Yasuo Ohashi 他
ESMO Open Cancer Horizons 2017.3
-
Assessment of Injection Site Reactions for Peripheral Intravenous Oxaliplatin Infusion and Potential Remedies.
Handa S, Kuroiwa R, Miyano M, Shimizu H, Kamei D, Takei H, Sonou H, Yamamoto H, Murayama J, Sato A, Kato Y
Gan to kagaku ryoho. Cancer & chemotherapy 43 ( 8 ) 985 - 8 2016.8
-
[Withdrawal of Anticancer Therapy in Advanced Disease Because of Side Effects].
Sato A, Chin Y, Kudo F, Saito K, Takahata T
Gan to kagaku ryoho. Cancer & chemotherapy 43 ( 7 ) 798 - 802 2016.7
-
Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer
Koichi Takayama,Shunichi Sugawara,Yasuo Saijo,Makoto Maemondo,Atsushi Sato,Shinzo Takamori,Taishi Harada,Tetsuro Sasada,Tatsuyuki Kakuma,Junji Kishimoto,Akira Yamada,Masanori Noguchi,Kyogo Itoh,and Yoichi Nakanishi
Journal of Immunology Reseach 7 - 7 2016.1
-
A Phase II Study of Third-Line Combination Chemotherapy with Bevacizumab Plus S-1 for Metastatic Colorectal Cancer with Mutated KRAS (SAVIOR Study).
Yoshida M, Takagane A, Miyake Y, Shimada K, Nagata N, Sato A, Ogata Y, Fukunaga M, Otsuka K, Takahashi T, Matsumoto H, Kagimura T, Tsuji A
Oncology 91 ( 1 ) 24 - 30 2016
-
Study protocol of the TRICOLORE trial:a randomized phase Ⅲ study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1,irinotecan,and bevacizumab as first-line therapy for metastatic colorectal cancer.
Yoshito Komatsu、Chikashi Ishioka、Ken Shimada、Yasuhide Yamada、Makio Gamoh、Atsushi Sato、Tatsuro Yamaguchi、Satoshi Yuki、Satoshi Morita、Shin Takahashi、Rei Goto and Minoru Kurihara
BMC Cancer 2015 Vol.15 15 626 - 626 2015.9
-
A phase II study of bevacizumab with modified OPTIMOX1 as first-line therapy for metastatic colorectal cancer: the TCOG-GI 0802 study.
Nakayama N, Sato A, Tanaka S, Shimada K, Konishi K, Sasaki E, Hibi K, Ichikawa H, Kikuchi Y, Sakuyama T, Sekikawa T, Hayashi K, Nishina H, Tokyo Cooperative Oncology Group, Tokyo, Japan.
Investigational new drugs 33 ( 4 ) 954 - 62 2015.8
-
A phase Ⅱ study of bevacizumab with modified OPTIMOX1 as first-line therapy for metastatic colorectal cancer:the TCOG-GI 0802 study.
Nakayama N、Sato A、Tanaka S、Shimada K、Konishi K、Sasaki E、Hibi K、Ichikawa H、Kikuchi Y、Sakuyama T、Sekikawa T、Hayashi K、Nishina H
Invest New Drugs 2015 Aug 33(4) 33 ( 4 ) 954 - 962 2015.5